Multidisciplinary Journal of Science and Technology

ASSESSMENT OF THE STATE OF POST-VACCINATION IMMUNITY TO MEASLES IN CHILDREN WITH POST-CAVID LONG SYNDROME AND OPTIMIZATION OF PREVENTIVE MEASURES TO REDUCE THE INCIDENCE OF MEASLES

Kenjayeva Dilorom Toshtemirovna

Termez branch of Tashkent medical academy

Keywords: children, juvenile idiopathic arthritis, vaccine prevention, antibody titer, measles, rubella, mumps, hepatitis B, diphtheria, risk factors.

---

Abstract

Patients with juvenile idiopathic arthritis (JIA) may have low protective levels of antibodies to vaccine antigens due to the immunologic features of the disease, disrupted vaccination schedules, and use of immunosuppressive medications. The purpose of the study was to study the state of post-vaccination immunity and determine the factors associated with the preservation of the protective level of antibodies in patients with JIA.

---

References

Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369(9563):767–778. doi: 10.1016/S0140-6736(07)60363-8.

Cassidy JT, Petty RE. Textbook of pediatric rheumatology. Elsevier Saunders; 2005. 792 р.

Beukelman T, Xie F, Chen L, et al; SABER Collaboration. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthrit Rheum. 2012;64(8):2773–2780. doi: 10.1002/art.34458.

Salvana EM, Salata RA. Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev. 2009;22(2):274–290. doi: 10.1128/CMR.00040-08.

Giancane G, Swart J, Bovis F, et al. Risk of infections in juvenile idiopathic arthritis patients treated with biologic agentsand/or methotrexate: results from pharmachild registry. Abstract number: 3116. Available from: https://acrabstracts.org/abstract/risk-ofinfections-in-juvenile-idiopathic-arthritis-patients-treated-withbiologic-agentsandor-methotrexate-results-from-pharmachildregistry/.

Abinun M, Lane JP, Wood M, et al. Infection-related death among persons with refractory juvenile idiopathic arthritis. Emerg Infect Dis. 2016;22(10):1720–1727. doi: 10.3201/eid2210.151245.

Castillo RD, De la Pena W, Marzan KA. Diagnosis and management of infectious complications of childhood rheumatic diseases. Curr Rheumatol Rep. 2013;15(4):322. doi: 10.1007/ s11926-013-0322-6.

Heijstek MW, Ott de Bruin LM, Bijl M, et al.; EULAR. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704–1712. doi: 10.1136/ ard.2011.150193.

Heijstek MW, van Gageldonk PG, Berbers GA, et al. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis. 2012;71(6):948–954. doi: 10.1136/annrheumdis-2011-200637.

Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–392.

МУ 3.1.2943-11 Организация и проведение серологического мониторинга состояния коллективного иммунитета к инфекциям, управляемым средствами специфической профилактики (дифтерия, столбняк, коклюш, корь, краснуха, эпидемический паротит, полиомиелит, гепатит В) [интернет]. [MU 3.1.2943-11 Organizatsiya i provedeniye serologicheskogo monitoringa sostoyaniya kollektivnogo immuniteta k infektsiyam, upravlyayemym sredstvami spetsificheskoy profilaktiki (difteriya, stolbnyak, koklyush, kor’, krasnukha, epidemicheskiy parotit, poliomiyelit, gepatit V). (In Russ).] Доступно по: http://docs.cntd.ru/document/1200088401. Ссылка активна на 12.04.2019.

Кощеева Ю.В., Харит С.М., Калинина Н.М. Особенности течения дифтерийного вакцинального процесса у детей с ревматическими заболеваниями // Журнал микробиологии, эпидемиологии и иммунобиологии. — 2001. — № 6. — С. 44–49. [Koshcheeva IV, Kharit SM, Kalinina NM. Specific features of diphtheria vaccinal process in children with rheumatic diseases. Journal of microbiology, epidemiology, and immunobiology. 2001;(6): 44–49. (In Russ).]

Харит С.М. Вакцинопрофилактика детей с иммунопатологическими заболеваниями // Фарматека. — 2003. — № 2. — С. 33–37. [Kharit SM. Vaktsinoprofilaktika detey s immunopatologicheskimi zabolevaniyami. Farmateka. 2003;(2):33–37. (In Russ).]

Heijstek MW, Kamphuis S, Armbrust W, et al. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA. 2013;309(23):2449–2456. doi: 10.1001/jama.2013.6768.

Клинико-лабораторная диагностика коревой инфекции. Информационное письмо № 16. — М., 2002. — 15 с. [Klinikolaboratornaya diagnostika korevoy infektsii. Informatsionnoye pis’mo №16. Moscow; 2002. 15 р. (In Russ).]

Заргарьянц А.И., Яковлева И.В., Селезнева Т.С., и др. Длительность и напряженность поствакцинального гуморального иммунитета к вирусам кори, паротита и краснухи // Эпидемиология и вакцинопрофилактика. — 2005. — № 5. — С. 15–19. [Zargar’yants AI, YAkovleva IV, Selezneva TS, et al. Dlitel’nost’ i napryazhennost’ postvaktsinal’nogo gumoral’nogo immuniteta k virusam kori, parotita i krasnukhi. Epidemiologiya i vaktsinoprofilaktika. 2005;(5):15–19. (In Russ).]

Шульгина Н.И., Стасенко В.Л. Оценка длительности и напряженности поствакцинального гуморального иммунитета к гепатиту В у лиц декретированных групп // Эпидемиология и вакцинопрофилактика. — 2011. — № 1. — С. 68–73. [Shulgina NI, Stasenko VL. Assessment of duration and intensity of post-vaccination humoral immunity to hepatitis B patients decreed groups. Epidemiologiya i vaktsinoprofilaktika. 2011;(1):68–73. (In Russ).]

Якимова Т.Н. Эпидемиологический надзор за дифтерией в Рос сии в период регистрации единичных случаев заболевания: Автореф. дис. канд. мед. наук. — М., 2015. — 22 с. [Yakimova TN. Epidemiologicheskiy nadzor za difteriyey v Rossii v period registratsii edinichnykh sluchayev zabolevaniya. [dissertation abstract] Moscow; 2015. 22 р. (In Russ).] Доступно по: https://search.rsl.ru/ ru/record/01006646046. Ссылка активна на 14.06.2019.

Kasapcopur O, Cullu F, Kamburoglu-Goksel A, et al. Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(9):1128–1130. doi: 10.1136/ard.2003.013201.

Borte S, Liebert UG, Borte M, et al. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford). 2009;48(2):144–148. doi: 10.1093/rheumatology/ken436.

Stoof SP, Heijstek MW, Sijssens KM, et al. Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study. Ann Rheum Dis. 2014;73(4):728–734. doi: 10.1136/ annrheumdis-2012-202561.

Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine. 2010;28(31):5109–5113. doi: 10.1016/j.vaccine.2010.03.080.

Groot N, Heijstek MW, Wulffraat NM. Vaccinations in paediatric rheumatology: an update on current developments. Curr Rheumatol Rep. 2015;17(7):46. doi: 10.1007/s11926-015-0519-y.

Miyamoto M, Ono E, Barbosa C, et al. Vaccine antibodies and T- and B-cell interaction in juvenile systemic lupus erythematosus. Lupus. 2011;20(7):736–744. doi: 10.1177/0961203310397409.

Ogimi C, Tanaka R, Saitoh A, Oh-Ishi T. Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J. 2011;30(3): 208–211. doi: 10.1097/INF.0b013e3181f7ce44.